First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant ...
With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...
Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...
Hundreds of Boston residents and some Boston University students who ended up in the emergency room with the norovirus this winter may take comfort in a recent research breakthrough that may help ...
Moderna's mRNA-1273 vaccine helped prevent medically attended COVID-19 and related hospitalizations across multiple respiratory seasons among adults.
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback